AAP
ANVS icon

Arax Advisory Partners’s Annovis Bio ANVS Stock Holding History

Arax Advisory Partners’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.92K Buy
4,000
+3,000
+300% +$8.23K ﹤0.01% 2502
2025
Q4 		$3.46K Buy
+1,000
New +$3.01K ﹤0.01% 3033

Other funds holding ANVS

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Arax Advisory Partners's ANVS Position: Q1 2026 in Review

Arax Advisory Partners increased its Annovis Bio (ANVS) stake by 300% in Q1 2026, buying an estimated $8.23K and bringing the position to 4,000 shares worth $8.92K. The position accounts for ﹤0.01% of the portfolio, ranked #2502.

Arax Advisory Partners first reported a position in ANVS in Q4 2025 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • Arax Advisory Partners held 4,000 shares of Annovis Bio worth $8.92K as of Q1 2026.
  • Arax Advisory Partners bought 3,000 Annovis Bio shares in Q1 2026, an estimated $8.23K.
  • Annovis Bio made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2502 holding.
  • Arax Advisory Partners first reported a position in Annovis Bio in Q4 2025 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.